Key Takeaways
- • Baker Brothers Advisors, a secretive biotech-focused hedge fund founded in 2000 by brothers Julian and Felix Baker, ranks as the 15th-largest U.S. hedge fund and counts Yale's endowment and the Tisch family among its institutional investors.
- • The fund maintained concentrated positions in biotech stocks through Q4 2022, with Seagen (a cancer therapy maker) representing its largest holding at approximately $6 billion in position value, having generated nearly 500% returns since initial acquisition in the early 2000s.
- • Baker Brothers manages a healthcare-only hedge fund with 115 stock holdings as of end-2022 and maintains a relatively low portfolio turnover rate, with its second-largest stake in biopharmaceutical company Incyte valued at $2.9 billion.
- • Yale's endowment has invested in Baker Brothers' 667 LP vehicle since at least 2009, while the Tisch family relationship extends back to 1994 when the brothers began managing healthcare sector investments on their behalf.
- • Despite managing significant assets and commanding elite institutional clients, Baker Brothers operates with minimal public profile—the brothers have never granted media interviews and the firm maintains no website.
Summary
Baker Brothers Advisors represents an atypical success story in institutional asset management: a fund commanding approximately $40+ billion in assets under management while maintaining near-total operational opacity. Founded in 2000 by immunology-trained brothers Julian and Felix Baker in New York, the hedge fund has built its 15th-place ranking among U.S. hedge funds primarily through concentrated biotech investing, leveraging the founders' scientific backgrounds during a decade of sector expansion.
The fund's client base includes some of America's most sophisticated institutional investors. Yale University's endowment has maintained a position in Baker Brothers' 667 LP vehicle since at least 2009, while the Tisch family relationship predates the hedge fund's founding—the brothers began managing healthcare investments for the family in 1994. Julian Baker's personal net worth has reached $2.6 billion, according to Forbes. Despite this pedigree and institutional prominence, Baker Brothers has cultivated an unusually private profile: neither founder has spoken to media, and the firm operates without a website.
As of Q4 2022, Baker Brothers' healthcare-only hedge fund held 115 stock positions with disciplined portfolio management reflected in relatively low turnover. The fund's largest position, biopharmaceutical company Seagen, carried a valuation of approximately $6 billion and has delivered outsized returns—the share price appreciated nearly 500% over the decade following the brothers' initial acquisition in the early 2000s. Incyte, a multinational biopharmaceutical business, represented the fund's second-largest stake at $2.9 billion in market value. This concentrated approach to biotech exposure, combined with the brothers' ability to identify transformative assets early in their commercial lifecycles, has defined the fund's investment thesis and institutional performance.
The fund's client base includes some of America's most sophisticated institutional investors. Yale University's endowment has maintained a position in Baker Brothers' 667 LP vehicle since at least 2009, while the Tisch family relationship predates the hedge fund's founding—the brothers began managing healthcare investments for the family in 1994. Julian Baker's personal net worth has reached $2.6 billion, according to Forbes. Despite this pedigree and institutional prominence, Baker Brothers has cultivated an unusually private profile: neither founder has spoken to media, and the firm operates without a website.
As of Q4 2022, Baker Brothers' healthcare-only hedge fund held 115 stock positions with disciplined portfolio management reflected in relatively low turnover. The fund's largest position, biopharmaceutical company Seagen, carried a valuation of approximately $6 billion and has delivered outsized returns—the share price appreciated nearly 500% over the decade following the brothers' initial acquisition in the early 2000s. Incyte, a multinational biopharmaceutical business, represented the fund's second-largest stake at $2.9 billion in market value. This concentrated approach to biotech exposure, combined with the brothers' ability to identify transformative assets early in their commercial lifecycles, has defined the fund's investment thesis and institutional performance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.